SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2017 / Cilt: 47 - Sayı: 5

EGFR, KRAS, and BRAF mutational profiles of female patients with micropapillary predominant invasive lung adenocarcinoma

Ülkü YILMAZ
Nilgün YILMAZ DEMİRCİ
Funda DEMİRAĞ
Aydın YILMAZ
Yurdanur ERDOĞAN
Pages
1354–1361
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

KRAS mutation was observed as having a similar frequency to what was previously observed, but the frequency of BRAF mutation was lower than previously reported.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: This study aimed to analyze EGFR, KRAS, and BRAF mutations in females with micropapillary predominant invasive lung adenocarcinoma and their relationships with immunohistochemical and clinicopathological patterns.
📊
Key Findings & Data:Materials and methods: A total of 15 females with micropapillary lung adenocarcinoma were selected.
💡
Conclusion & Impact:KRAS mutation was observed as having a similar frequency to what was previously observed, but the frequency of BRAF mutation was lower than previously reported.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: This study aimed to analyze EGFR, KRAS, and BRAF mutations in females with micropapillary predominant invasive lung adenocarcinoma and their relationships with immunohistochemical and clinicopathological patterns. Materials and methods: A total of 15 females with micropapillary lung adenocarcinoma were selected. Mutational analysis of the EGFR, KRAS, and BRAF genes was carried out. Information regarding the demographic data, tumor size, treatment, and survival time for each patient was collated, and the predominant cell type, secondary architectural growth patterns, psammoma bodies, necrosis, and visceral pleural and angiolymphatic invasions were evaluated. Results: We identified EGFR mutation in six cases, KRAS mutation in three cases, and BRAF mutation in one case. EGFR, c-kit, VEGFR, and bcl-2 positivity was observed in ten, seven, four, and six cases, respectively. All cases were positive for VEGF (strong positivity in 11 cases and weak positivity in four cases) and bcl-2 (strong positivity in nine cases and weak positivity in six cases). Seven (46.6%) cases were positive for c-kit and 10 (66.6%) cases were positive for EGFR. Conclusion: EGFR mutation occurred at a higher incidence rate in micropapillary predominant invasive adenocarcinoma than has previously been found in conventional lung adenocarcinomas. KRAS mutation was observed as having a similar frequency to what was previously observed, but the frequency of BRAF mutation was lower than previously reported.

🔖

Cite This Article

YILMAZ, Ü., DEMİRCİ, N. Y., DEMİRAĞ, F., YILMAZ, A., ERDOĞAN, Y. (2022). EGFR, KRAS, and BRAF mutational profiles of female patients with micropapillary predominant invasive lung adenocarcinoma. Turkish Journal of Medical Sciences, Cilt: 47 - Sayı: 5, 1354–1361. https://ajindex.com/articles/610463

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Siegel R, Naishadham D, Jemal A. Cancer Statistics. CA-Cancer J Clin 2012; 62: 10-29
  2. Kerr KM. Pulmonary adenocarcinomas: classification and reporting. Histopathology 2009; 54: 12-27
  3. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, Beer DG, Powell CA, Riely GJ, Yan Schil PE et al. International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011; 6: 244-285
  4. Tsutsumida H, Nomoto M, Goto M, Kitajima S, Kubota I, Hirotsu Y, Wakimoto J, Hollingsworth MA, Yonezawa S. A micropapillary pattern is predictive of a poor prognosis in lung adenocarcinoma, and reduced surfactant tapoprotein A expression in the micropapillary pattern is an excellent indicator of a poor prognosis. Modern Pathol 2007; 20: 638- 647
  5. Reungwetwattana T, Weroha SJ, Molina JR. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). Clin Lung Cancer 2012; 13: 252-266
  6. Achcar ROD, Nikforova MN, Yousem SA. Micropapillary lung adenocarcinoma, EGFR, K-ras, and BRAF mutational profile. Am J Clin Pathol 2009; 131: 694-700
  7. Zhang J, Liang Z, Gao J, Luo Y, Liu T. Pulmonary adenocarcinoma with a micropapillary pattern: a clinicopathological, immunophenotypic and molecular analysis. Histopathology 2011; 59: 1204-1214
  8. Ohe M, Yokose T, Sakuma Y, Miyagi Y, Okamoto N, Osanai S, Hasegawa C, Nakayama H, Kameda Y, Yamada K et al. Stromal micropapillary component as a novel unfavorable prognostic factor of lung adenocarcinoma. Diagn Pathol 2012; 7: 3
  9. Motoi N, Szoke J, Riely GJ, Seshan WE, Kris MG, Rusch VW, Gerald WL, Trawis WD. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008; 32: 810-827
  10. Li H, Pan Y, Li Y, Li C, Wang R, Hu H, Zhang Y, Ye T, Wang L, Shen L et al. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. Lung Cancer 2013; 79: 8-13
  11. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest 2009; 136: 260-271
  12. Törmӓnen-Nӓpӓnkangas U, Soini Y, Kahlos K, Kinnula V, Pӓӓkkö P. Expression of caspases-3, -6 and -8 and their